# Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Source: https://onco.cc/trials/nct05220722/  
OnCo record `nct05220722` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Nelitolimod run by TriSalus Life Sciences, Inc., terminated.

## Summary

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors is a phase 1/2 interventional study registered as NCT05220722 by TriSalus Life Sciences, Inc., with 23 participants enrolled, started 2022-03-02, primary completion reached 2024-07-31. Conditions recorded: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma. Interventions recorded: SD-101, Pembrolizumab, Nivolumab, Ipilimumab. Reason given for stopping: The decision was made to terminate the study after the completion of Phase 1b enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05220722
- Phase: 1/2
- Setting: A Phase 1b/2 Pressure Enabled Regional Immuno-Oncology Study of Hepatic Arterial Infusion of SD-101 With Systemic Checkpoint Blockade for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
- Sponsor: TriSalus Life Sciences, Inc.
- Enrolled: 23

## Sources

- ClinicalTrials.gov NCT05220722: https://clinicaltrials.gov/study/NCT05220722

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- drugs: [Nelitolimod](https://onco.cc/drugs/nelitolimod/)
- companies: [TriSalus Life Sciences](https://onco.cc/companies/trisalus-life-sciences/)

---
JSON: https://onco.cc/api/v1/entities/nct05220722.json